Alexander MacDonald
AstraZeneca
15 Papers
18 Citations
Alexander MacDonald is an academic researcher from AstraZeneca. The author has contributed to research in topics: Bone marrow & Medicine. The author has an hindex of 4, co-authored 13 publications.
Chat about Author
Papers
On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology.
David B. Chou,David B. Chou,Viktoras Frismantas,Yuka Milton,Rhiannon David,Petar Pop-Damkov,Douglas Ferguson,Alexander MacDonald,Özge Vargel Bölükbaşı,Cailin E. Joyce,Liliana Moreira Teixeira,Arianna Rech,Arianna Rech,Amanda Jiang,Elizabeth Calamari,Sasan Jalili-Firoozinezhad,Sasan Jalili-Firoozinezhad,Brooke A. Furlong,Lucy R. O’Sullivan,Carlos F. Ng,Youngjae Choe,Susan Marquez,Kasiani C. Myers,Kasiani C. Myers,Olga K. Weinberg,Robert P. Hasserjian,Richard M. Novak,Oren Levy,Rachelle Prantil-Baun,Carl D. Novina,Carl D. Novina,Akiko Shimamura,Lorna Ewart,Donald E. Ingber,Donald E. Ingber,Donald E. Ingber +35 more
TL;DR: A vascularized human bone-marrow-on-a-chip improves the maintenance of patient-derived CD34 + cells, and recapitulates clinically relevant aspects of bone marrow injury as well as key haematopoietic defects of patients with a rare genetic disorder.
A Randomized, Open-label, Presurgical, Window-of-Opportunity Study Comparing the Pharmacodynamic Effects of the Novel Oral SERD AZD9496 with Fulvestrant in Patients with Newly Diagnosed ER+ HER2- Primary Breast Cancer.
John F.R. Robertson,Abigail Evans,S. Henschen,Cliona C. Kirwan,A Jahan,Laura M. Kenny,J Michael Dixon,Peter Schmid,Ashutosh Kothari,Omar Mohamed,Peter A. Fasching,Kwok-Leung Cheung,Rachel Wuerstlein,Danielle Carroll,Teresa Klinowska,Justin P.O. Lindemann,Alexander MacDonald,Richard Mather,Rhiannon Maudsley,Michele Moschetta,Myria Nikolaou,Martine P. Roudier,Tinnu Sarvotham,Gaia Schiavon,Diansong Zhou,Li Zhou,Nadia Harbeck +26 more
TL;DR: This was the first presurgical study to demonstrate that an oral SERD affects its key biological targets, however, AZD9496 was not superior to fulvestrant at the dose tested.
Target engagement and cellular fate of otelixizumab; a repeat dose escalation study of an anti‐CD3ε mAb in New‐Onset Type 1 Diabetes Mellitus Patients
Georgios Vlasakakis,Antonella Napolitano,Ruth M Barnard,Kim Brown,Jonathan Bullman,David Inman,Bart Keymeulen,David Lanham,Quentin Leirens,Alexander MacDonald,Enrica Mezzalana,Kevin R. Page,Minesh Patel,Caroline O. S. Savage,Stefano Zamuner,André van Maurik +15 more
TL;DR: The pharmacological findings from a study where otelixizumab, an anti‐CD3ɛ mAb, was dosed in new onset Type 1 diabetes mellitus (NOT1DM) patients are described.
10
Author Correction: On-chip recapitulation of clinical bone marrow toxicities and patient-specific pathophysiology
David B. Chou,Viktoras Frismantas,Yuka Milton,Rhiannon David,Petar Pop-Damkov,Douglas Ferguson,Alexander MacDonald,Özge Vargel Bölükbaşı,Cailin E. Joyce,Liliana Moreira Teixeira,Arianna Rech,Arianna Rech,Amanda Jiang,Elizabeth Calamari,Sasan Jalili-Firoozinezhad,Sasan Jalili-Firoozinezhad,Brooke A. Furlong,Lucy R. O’Sullivan,Carlos F. Ng,Youngjae Choe,Susan Marquez,Kasiani C. Myers,Kasiani C. Myers,Olga K. Weinberg,Robert P. Hasserjian,Richard M. Novak,Oren Levy,Rachelle Prantil-Baun,Carl D. Novina,Carl D. Novina,Akiko Shimamura,Lorna Ewart,Donald E. Ingber +32 more
TL;DR: An amendment to this paper has been published and can be accessed via a link at the top of the paper.
A phase I, open-label, first-time-in-patient dose escalation and expansion study to assess the safety, tolerability, and pharmacokinetics of nanoparticle encapsulated Aurora B kinase inhibitor AZD2811 in patients with advanced solid tumours.
Howard A. Burris,Judy Sing-Zan Wang,Melissa Lynne Johnson,Gerald Steven Falchook,Suzanne F. Jones,Donald K Strickland,Carol Greenlees,Wolfram Brugger,Julie Charlton,Elizabeth Janet Pease,Alexander MacDonald +10 more
TL;DR: AZD2811, formerly designated AZD1152 hydroxy-quinazoline pyrazole anilide (AZD11 52 hQPA), is a potent and selective inhibitor of Aurora B kinase activity and has been incorporated into a polymer nanoparticle carrier for intravenous (IV) administration.
8